APYX

SEC filing APYX Reports New Study Showing 81.8% Improvement in Cellulite Appearance with Avéli and Renuvion Treatment, Demonstrating Measurable Reductions in Dimple Volume and Increased Collagen/Elastin

11d ago

News Butterfly Network's Stock Surges on iQ3 Device Launch in Europe

14d ago

SEC filing Other Events

19d ago

SEC filing APYX Reports $12.5M Q1 Rev, $2.1M Net Loss, Raises FY2026 Rev Guidance to $59-60M, +36% YoY Surgical Aesthetics Growth, +62.9% Intl Sales Surge, Renuvion Wins 2026 NewBeauty Award

26d ago

News Apyx Medical outlines 9%–11% revenue growth target for 2026 as AYON launch accelerates

84d ago

News Apyx Medical reports preliminary Q4 revenue up about 34%

141d ago

News Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock

156d ago